Autres langues Rezolute, Inc.

Actions

RZLT

US76200L3096

Temps Différé Nasdaq Autres places de cotation 21:55:30 06/05/2024			Varia. 5j.	Varia. 1 janv.
3,27 ^USD	-1,21 %		+25,29 %	+229,47 %

18/04	REZOLUTE, INC. : JonesTrading Institutional Services toujours à l'achat	ZM
06/03	Rezolute, Inc. annonce la validation de l'utilisation potentielle du RZ358 pour le traitement de l'hypoglycémie non liée à une tumeur des îlots de Langerhans (NICTH)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

REZOLUTE, INC. - PHASE 2 RIZE STUDY SUB-ANALYSES TO BE PRESENTED AT THE 2024 PEDIATRIC ENDOCRINE SOCIETY ANNUAL MEETING	24/04
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	23/04
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting	23/04
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA	07/03
Rezolute : Corporate Presentation – March 2024	06/03
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	06/03
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)	06/03
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia	06/03
Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update	13/02
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	24/01
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer	24/01
Rezolute, Inc. Appoints Daron Evans as Chief Financial Officer	24/01
REZOLUTE RECEIVES INNOVATION PASSPORT DESIGNATION FROM THE U.K. INNOVATIVE LICENSING AND ACCESS PATHWAY STEERING GROUP FOR RZ358	24/01
Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	23/01
Rezolute, Inc. Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism	23/01
Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism	14/12
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)	13/12
Rezolute, Inc. Announces Completion of Enrollment in its RZ402 Phase 2 Study in Diabetic Macular Edema	13/12
Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an "XBI-MAS"	24/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Rezolute, Inc.

Actions

RZLT

US76200L3096

Autres langues

Filtres